Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation

Haematologica

Volumn 97, Issue 3, 2012, Pages

  Milojkovic, Dragana ^a   Ibrahim, Amr ^a   Reid, Alistair ^a   Foroni, Letizia ^a   Apperley, Jane ^a   Marin, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Blastic phase; Chronic myeloid leukemia; Dasatinib; FLAG IDA

Indexed keywords

CYTARABINE; DASATINIB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VIDARABINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MALE; NEUTROPHIL COUNT; REMISSION; TREATMENT RESPONSE; AGED; BLAST CELL CRISIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME; VIDARABINE;

EID: 84857752508     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.057513     Document Type: Letter

References (9)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-42.
2. Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852-61.
3. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207-13.
4. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99(7):2304-9.
5. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 2002;16(12):2349-57.
6. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97(7):1999-2007.
7. Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002;94(10):2653-62.
8. Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2010;35(6):777-82.
9. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006;20(3):400-3.